Tempus Wealth Planning LLC Buys Shares of 21,320 Evolent Health, Inc. (NYSE:EVH)

Tempus Wealth Planning LLC purchased a new position in Evolent Health, Inc. (NYSE:EVH) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 21,320 shares of the technology company’s stock, valued at approximately $240,000.

Several other hedge funds also recently made changes to their positions in EVH. Wellington Management Group LLP lifted its holdings in shares of Evolent Health by 12.8% in the third quarter. Wellington Management Group LLP now owns 12,595,459 shares of the technology company’s stock worth $356,200,000 after buying an additional 1,426,747 shares in the last quarter. Point72 Asset Management L.P. increased its holdings in Evolent Health by 1,948.5% during the 3rd quarter. Point72 Asset Management L.P. now owns 1,495,385 shares of the technology company’s stock worth $42,289,000 after acquiring an additional 1,422,385 shares during the period. Bellevue Group AG boosted its holdings in Evolent Health by 59.9% in the 3rd quarter. Bellevue Group AG now owns 2,670,050 shares of the technology company’s stock valued at $75,509,000 after purchasing an additional 1,000,215 shares during the period. Harbor Capital Advisors Inc. grew its position in shares of Evolent Health by 90.1% during the 4th quarter. Harbor Capital Advisors Inc. now owns 803,211 shares of the technology company’s stock valued at $9,036,000 after purchasing an additional 380,790 shares in the last quarter. Finally, Foundry Partners LLC purchased a new stake in shares of Evolent Health in the third quarter worth $10,042,000.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on EVH. KeyCorp assumed coverage on shares of Evolent Health in a research report on Friday, October 11th. They issued an “overweight” rating and a $35.00 price objective on the stock. Royal Bank of Canada lowered their price objective on shares of Evolent Health from $20.00 to $17.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 14th. Stephens dropped their price objective on shares of Evolent Health from $16.00 to $12.00 and set an “equal weight” rating for the company in a report on Tuesday, January 21st. Truist Financial lowered their price target on Evolent Health from $20.00 to $15.00 and set a “buy” rating on the stock in a research report on Wednesday, January 22nd. Finally, UBS Group cut their price objective on Evolent Health from $27.00 to $14.00 and set a “buy” rating for the company in a report on Thursday, January 16th. One analyst has rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $18.38.

Evolent Health Trading Up 0.5 %

Shares of EVH opened at $10.27 on Wednesday. The stock has a market capitalization of $1.20 billion, a P/E ratio of -11.28 and a beta of 1.45. Evolent Health, Inc. has a twelve month low of $9.74 and a twelve month high of $35.00. The company has a quick ratio of 1.04, a current ratio of 1.04 and a debt-to-equity ratio of 0.58. The firm has a fifty day simple moving average of $11.22 and a two-hundred day simple moving average of $19.91.

Evolent Health (NYSE:EVH) last posted its earnings results on Thursday, November 7th. The technology company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.30 by ($0.38). The business had revenue of $621.40 million during the quarter, compared to the consensus estimate of $625.58 million. Evolent Health had a positive return on equity of 6.30% and a negative net margin of 2.93%. During the same period in the previous year, the business earned $0.19 earnings per share. On average, research analysts anticipate that Evolent Health, Inc. will post 0.24 EPS for the current year.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.